We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Phase II investigation of a PARP inhibitor (olaparib) in castration resistant prostate cancer (CRPC) which incorporates the possibility that treatment effect may be restricted to biomarker defined subgroups.
- Authors
A'Hern, Roger; DeBono, Johann; Sandhu, Shahneen; Kalaitzaki, Eletheria; Usdin, Martine; Hall, Emma E.
- Abstract
An abstract of the article "Phase II investigation of a PARP inhibitor (olaparib) in castration resistant prostate cancer (CRPC) which incorporates the possibility that treatment effect may be restricted to biomarker defined subgroups," by Roger A'Hern and colleagues, is presented.
- Subjects
CLINICAL trials; PROSTATE cancer
- Publication
Trials, 2011, Vol 12, Issue Suppl 1, p1
- ISSN
1745-6215
- Publication type
Abstract
- DOI
10.1186/1745-6215-12-S1-A88